A Cure For Back Pain? Phase II Clinical Trials Begin For Promising Drug Candidate

Dr. Jason Lipetz, MD, Physiatrist & Head of Spine Medicine at Northwell Health, was recently interviewed by Benzinga. Dr. Lipetz is currently assisting BioRestorative Therapies, Inc BRTX in phase 2 trials of a novel therapy for degenerative disc disease, BRTX-100.

BioRestorative Therapies is a biotechnology company focused on creating stem cell therapies to address unmet needs. The company’s technology harnesses the power of a patient's own regenerative potential to aid in conditions from back pain to metabolic disease.

BRTX-100 is a novel treatment for cLDD – chronic lumbar disc disease – a debilitating condition affecting millions across the globe. Marked by back pain, stiffness and restricted movement, cLDD is a serious condition that greatly impacts a person’s quality of life. BioRestorative Therapies reports that BRTX-100 has shown promising results in using the body’s own power to heal itself.

Watch the full interview here:

Featured photo by Louis Reed on Unsplash.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.